Commission Implementing Decision (EU) 2016/1190 of 19 July 2016 authorising the placing on the market of trans-resveratrol as a novel food ingredient under Regulation (EC) No 258/97 of the European Parliament and of the Council (notified under document C(2016) 4567) (Only the English text is authentic)
Grade B
mapped from publisher markup. A grade says how a document's structure was obtained, not how reliable the law is.
Address https://gelex.eu/eli/EU/decision/2016/1190@2016-07-19/en
THE EUROPEAN COMMISSION,
Having regard to the Treaty on the Functioning of the European Union,
Having regard to Regulation (EC) No 258/97 of the European Parliament and of the Council of 27 January 1997 concerning novel foods and novel food ingredients, and in particular Article 7 thereof,
Whereas:
(1) On 8 November 2012, the company DSM Nutritional Products Ltd made a request to the competent authorities of Ireland to place trans-resveratrol on the market as a novel food ingredient within the meaning of point (f) of Article 1(2) of Regulation (EC) No 258/97.
(2) On 28 June 2013, the competent food assessment body of Ireland issued its initial assessment report. In that report it came to the conclusion that trans-resveratrol meets the criteria for novel food ingredients set out in Article 3(1) of Regulation (EC) No 258/97.
(3) On 4 September 2013, the Commission forwarded the initial assessment report to the other Member States.
(4) Reasoned objections were raised within the 60-day period laid down in the first subparagraph of Article 6(4) of Regulation (EC) No 258/97.
(5) On 3 April 2014, the Commission consulted the European Food Safety Authority (EFSA) asking it to carry out an additional assessment for trans-resveratrol as novel food ingredient in accordance with Regulation (EC) No 258/97.
(6) On 11 December 2015, EFSA concluded in its opinion on the safety of synthetic trans-resveratrol as a novel food, that trans-resveratrol used in food supplements intended for adults is safe under the proposed conditions of use.
(7) That opinion gives sufficient grounds to establish that trans-resveratrol as a novel food ingredient complies with the criteria laid down in Article 3(1) of Regulation (EC) No 258/97.
(8) In its opinion, EFSA also indicated that trans-resveratrol may interact with specific medicines therefore, it is necessary to inform the consumers when consumed in combination with medicines.
(9) Directive 2002/46/EC of the European Parliament and of the Council lays down requirements for food supplements. The use of trans-resveratrol should be authorised without prejudice to that legislation.
(10) The measures provided for in this Decision are in accordance with the opinion of the Standing Committee on Plants, Animals, Food and Feed,
HAS ADOPTED THIS DECISION:
Article 1
Trans-resveratrol as specified in the Annex to this Decision may be placed on the market in the Union as a novel food ingredient to be used in food supplements in capsule or tablet form intended for adult population only with a maximum dose of 150 mg per day without prejudice to the provisions of Directive 2002/46/EC.
Article 2
1. The designation of trans-resveratrol authorised by this Decision on the labelling of the foodstuffs containing it shall be trans-resveratrol.
2. The labelling of food supplements containing trans-resveratrol shall bear a statement that people using medicines should only consume the product under medical supervision.
Article 3
This Decision is addressed to DSM Nutritional Products Ltd, Heanor Gate Ind. Est. Heanor, Derbyshire, United Kingdom.
Done at Brussels, 19 July 2016. For the Commission Vytenis Andriukaitis Member of the Commission
ANNEX
ANNEX SPECIFICATION OF TRANS-RESVERATROL
Description: Trans-resveratrol is off-white to beige crystals.
Definition:
Chemical name 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol Chemical formula C14H12O3 Molecular weight 228,25 Da CAS No 501-36-0
Purity:
Trans-resveratrol Not less than 99 % Total by-products (related substances) Not more than 0,5 % Any single related substance Not more than 0,1 % Lead Not more than 1 ppm Mercury Not more than 0,1 ppm Cadmium Not more than 0,5 ppm Arsenic Not more than 1 ppm Loss on drying Not more than 0,5 % Sulphated ash Not more than 0,1 % Diisopropylamine Not more than 50 mg/kg
Versions
Cited by
- Commission Implementing Regulation (EU) 2022/672 of 22 April 2022 amending Implementing Regulation (EU) 2017/2470 as regards the specifications of the novel food trans-resveratrol (from microbial source) (Text with EEA relevance) Regulation · Grade B
Commission Implementing Decision (EU) 2016/1190 authorised the placing on the Union market of synthetic trans-resveratrol as a novel food ingredient under Regulation (EC) No 258/97, also to be used in food supplements as defined in Directive 2002/46/EC in capsule or tablet form, for the adult population.
- Commission Implementing Regulation (EU) 2021/51 of 22 January 2021 authorising a change of the conditions of use of the novel food trans-resveratrol under Regulation (EU) 2015/2283 of the European Parliament and of the Council and amending Commission Implementing Regulation (EU) 2017/2470 (Text with EEA relevance) Regulation · Grade B
Commission Implementing Decision (EU) 2016/1190 authorised the placing on the Union market of trans-resveratrol as a novel food ingredient under Regulation (EC) No 258/97 of the European Parliament and of the Council, to be used in food supplements as defined in Directive 2002/46/EC of the European Parliament and of the Council, in capsule or tablet form, for the adult population.
- Commission Implementing Regulation (EU) 2021/51 of 22 January 2021 authorising a change of the conditions of use of the novel food trans-resveratrol under Regulation (EU) 2015/2283 of the European Parliament and of the Council and amending Commission Implementing Regulation (EU) 2017/2470 (Text with EEA relevance) Regulation · Grade B
The maximum level of trans-resveratrol in food supplements authorised by Implementing Decision (EU) 2016/1190 and indicated in the Union list of novel foods remains the same. The safety considerations that supported the authorisation of trans-resveratrol in food supplements remain valid and the removal of the specific delivery formats of food supplements does not pose safety concern.